Roche to buy autoimmune drugmaker from Pfizer, Roivant for $7B
Roche has agreed to acquire Telavant Holdings, maker of an inflammatory bowel disease drug, from Roivant Sciences and Pfizer for $7.25 billion.
Source: beckershospitalreview.com
📰 Phase 3 News
Page 6 - Phase 3 News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Phase 3. Real-time updates on events, politics, business and more.
Filgotinib Misses Co-Primary Endpoints in Phase 3 DIVERSITY1 Study, Presented at ACG 2023
Presented in an abstract at ACG 2023, filgotinib missed both co-primary endpoints at week 10 but was efficacious at week 52 in the maintenance cohorts.
British Columbia American College Of Gastroenterology American College Scientific Meeting Disease Activity Index Maintenance Therapy
Source: hcplive.com
Live Microbiota Therapy Prevents Recurrent CDI in Older Adults with Comorbidity
New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.
British Columbia Andrew Skinner Cirlea Warren American College Of Gastroenterology Loyola University University Of Virginia
Source: hcplive.com
Majority of Atopic Dermatitis Patients Maintained Clear Skin with Lebrikizumab Over 2 Years
These findings, presented at the Fall Clinical Dermatology conference, resulted from the ADjoin long-term extension study.
Source: hcplive.com
Low-Dose Amitriptyline Offers Viable Second-Line Treatment for IBS
Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.
Hazel Everitt University Of Southampton Care Research Centre University Of Southampton Hazel Everitt University Of Leeds United European Gastroenterology Week
Source: hcplive.com
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.
New Zealand Republic Of Carlo Montagner Canariabio Inc Gynecologic Oncology Group Foundation Shenzhen Hepalink Pharmaceuticals Group Company
Source: yahoo.com
Phase 3 Data on Bimekizumab for Hidradenitis Suppurativa Show Meaningful Improvements
The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.
United States Hidradenitis Suppurativa European Hidradenitis Suppurativa Foundation Brandenburg Medical School American Academy Of Dermatology European Academy Of Dermatology
Source: hcplive.com
Q Casino's Next Phase of Expansions Approved In Dubuque, IA
Discover Dubuque's Q Casino's multi-year makeover as it embarks on Phases 2 and 3, part of a $75-80 million revitalization plan to reshape Schmitt Island.
United States City Of Dubuque Steve Pulaski Brian Rakestraw Gaming Commission Dubuque Racing Association
Source: krna.com
Q Casino's Next Phase of Expansions Approved In Dubuque, IA
Discover Dubuque's Q Casino's multi-year makeover as it embarks on Phases 2 and 3, part of a $75-80 million revitalization plan to reshape Schmitt Island.
United States City Of Dubuque Steve Pulaski Brian Rakestraw Dubuque Racing Association Gaming Commission
Source: khak.com
Iptacopan Achieves Primary Endpoint for Proteinuria Reduction in Patients with IgAN
Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.
Novartis Shreeram Aradhye Shreeram Aradhye Norvartis Pharmaceuticals Drug Administration Chief Medical Officer Applause Igan
Source: hcplive.com